SCHEMBL2016799

SCHEMBL2016799

CC1(C)CCC(C)(C)c2cc(-c3ncnc(N4CCN(CCCCO)CC4)n3)ccc21

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 1/20 0.42
RARB P10826 6/20 0.40
RARG P13631 5/20 0.40
RARA P10276 5/20 0.40
RXRA P19793 1/20 0.37
NR1H4 Q96RI1 1/20 0.37
SCN9A Q15858 1/20 0.36
LRRK2 Q5S007 3/20 0.35
HRH3 Q9Y5N1 2/20 0.35
ACHE P22303 1/20 0.35
HTR1A P08908 2/20 0.35
HTR7 P34969 1/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
HTR2A P28223 1/20 0.34
DRD3 P35462 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12959442 0.99 HRH4 (0.42) HRH4RARBRARGRARARXRA
SCHEMBL2013272 0.86 HRH3 (0.43) HRH4RARBRARGRARAHRH3
SCHEMBL2012292 0.85 ACHE (0.40) RARBRARGRARAHRH3ACHE
SCHEMBL2017376 0.84 CYP1A2 (0.41) RARBRARGRARALRRK2HRH3
SCHEMBL2016809 0.84 ACHE (0.39) RARBRARGRARAHRH3ACHE
SCHEMBL12804934 0.83 HRH4 (0.38) HRH4RARBRARGRARARXRA
SCHEMBL2014225 0.83 CYP1A2 (0.40) RARBRARGRARALRRK2HRH3
SCHEMBL12805574 0.82 RARB (0.43) HRH4RARBRARGRARARXRA
SCHEMBL2014854 0.82 ACHE (0.41) RARBRARGRARALRRK2HRH3
SCHEMBL12633170 0.81 CYP1A2 (0.42) RARBRARGRARARXRALRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9062015-B2 Inhibitors of sphingosine kinase MERCK PATENT GMBH (DE) 2015-06-23 US disclosed
US-9062015-B2 Inhibitors of sphingosine kinase MERCK PATENT GMBH (DE) 2015-06-23 US disclosed
US-9062015-B2 Inhibitors of sphingosine kinase MERCK PATENT GMBH (DE) 2015-06-23 US disclosed
EP-2513057-B1 SPHINGOSINE KINASE INHIBITORS MERCK PATENT GMBH (DE) 2013-09-04 EP disclosed
EP-2513057-B1 SPHINGOSINE KINASE INHIBITORS MERCK PATENT GMBH (DE) 2013-09-04 EP disclosed
EP-2513057-A1 SPHINGOSINE KINASE INHIBITORS Merck Patent GmbH (DE) 2012-10-24 EP disclosed
US-20120252789-A1 INHIBITORS OF SPHINGOSINE KINASE MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-10-04 US disclosed
US-20120252789-A1 INHIBITORS OF SPHINGOSINE KINASE MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-10-04 US disclosed
US-20120252789-A1 INHIBITORS OF SPHINGOSINE KINASE MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-10-04 US disclosed
WO-2011072791-A1 SPHINGOSINE KINASE INHIBITORS MERCK PATENT GMBH (DE) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120252789-A1 INHIBITORS OF SPHINGOSINE KINASE SPHK1, SPHK2, S1PR3 HRH4 419/4885RARB 4194/4885RARG 4187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.